跳至主要内容
临床试验/ITMCTR2100004896
ITMCTR2100004896招募中1 期

A randomized, double-blind, placebo-controlled trial of Qidong Bufei Decoction in treating postoperative symptoms of non-small cell lung cancer

Guang'anmen Hospital, China Academy of Chinese Medical Sciences.0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • 1. Postoperative patients with stage I non-small cell lung cancer diagnosed by pathology or cytology;
  • 2. Enroll in the group within two weeks after thoracoscopy;
  • 3. Aged 18-75 years;
  • 4. Physical condition score ECOG 0-2 points;
  • 5. Estimated survival period >= 6 months;
  • 6. Neutrophils>1.5x10^9/L, platelets > 100x10^9/L, hemoglobin>9.0g/dl; normal bilirubin or < 1.5xULN; AST (SGOT), ALT (SGPT)< 2.5xULN; serum creatinine < 1.5xULN.

排除标准

  • 1. Patients who received neoadjuvant chemotherapy before surgery;
  • 2. Those who intend to receive radiotherapy, chemotherapy, targeted drug therapy and other treatment methods within 1 month after surgery;
  • 3. Patients with severe complications such as pulmonary embolism, respiratory failure, and myocardial infarction during the perioperative period;
  • 4. In other clinical trials;
  • 5. Patients during pregnancy or lactation;
  • 6. Patients with a history of mental illness that is difficult to control;
  • 7. Those who are allergic to study drugs;
  • 8. Those who cannot understand and refuse to sign the informed consent form;
  • 9. Those who cannot cooperate with the scale data collector.

研究者

相似试验

A randomized, double-blind, placebo-controlled trial... | 临床试验